As Authorized Generics Proliferate, Benefits Are Unclear

Pharmaceutical manufacturers likely will continue to turn to authorized generics — drugs produced by brand-name drugmakers without the brand label — as they face increased pushback against high drug prices, but payers and patients probably won’t see much benefit as a result, according to industry experts.

“I think we will continue to see authorized generics competing with traditional generics,” says Stacie Dusetzina, Ph.D., associate professor of health policy at Vanderbilt University School of Medicine. “I’m hopeful that we will see fewer signs that they are being used in pay-for-delay types of arrangements or to discourage traditional generic competition.”

© 2021 MMIT

Freelance Reporter Freelance Reporter

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-Merck-COVID-19-Drug-Could-Gain-Emergency-Use-Authorization.jpg
October 14

Merck COVID-19 Drug Could Gain Emergency Use Authorization

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-More-MA-PD-PDP-Members-Will-Be-in-4-Star-Plans-in-2022.jpg
October 14

More MA-PD, PDP Members Will Be in 4-Star Plans in 2022

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-drug-benefits-PhRMA-Blasts-Poll-About-Govt-Drug-Price-Negotiation-Support.jpg
October 14

PhRMA Blasts Poll About Gov’t Drug Price Negotiation Support

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today